Our analysis of this real-world cohort suggests that earlier access to a molecular diagnosis of EGFR-related lung cancer is expected to decrease complications and hospitalizations related to delays in initiation of therapy and avoid early deaths. The gene discussed is EGFR; the disease is lung carcinoma.